[Preclinical Alzheimer's Disease]

Preclinical Alzheimer's Disease has been an evolving concept and understanding within the Alzheimer's disease community for about 20 years. The recurrent postprandial hyperammonemia of neurotoxic ammonia from dysbiosis over decades with accumulating neural damage, explains this hypothesis. This is like "death by 1000 cuts."

Diagnosis of preclinical Alzheimer's disease with the Ammonia Challenge Test could identify patients at risk of developing Alzheimer's cognitive decline as they age. (Simple 25 mg protein shake and a serum ammonia test 3 hours after done in any hospital laboratory.)

Therapy with neurotoxic ammonia binding CHELATEXX and CHELATEXX VIT-C, both OTC Drugs under monograph, could decrease this risk of progressive decline. Monitoring CHELATEXX and CHELATEXX VIT-C therapy with the same Ammonia Challenge Test could confirm Therapy success to PREVENT progressive cognitive decline.

Reference Links:

1. "Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria"
   www.pubmed.gov/27012484
2. "Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility"
   www.pubmed.gov/27702678
3. "Biomarkers for preclinical Alzheimer's disease"
   www.pubmed.gov/25024325
4. "The critical need for defining preclinical biomarkers in Alzheimer's disease"
   www.pubmed.gov/24924671
5. "The 12 years Preceding Mild Cognitive Impairment Due to Alzheimer's disease: The Temporal Emergence of Cognitive Decline"
   www.pubmed.gov/26402083